brigimadlin + ezabenlimab + BI 754111

Brigimadlin + ezabenlimab + BI 754111 is a combination regimen involving three investigational agents developed by Boehringer Ingelheim: - **Brigimadlin (BI 907828):** An oral small-molecule inhibitor that antagonizes MDM2–p53 interaction, restoring p53 tumor suppressor activity and inducing cell-cycle arrest and apoptosis in TP53 wild-type tumors. - **Ezabenlimab (BI 754091):** A monoclonal antibody targeting the programmed death-1 (PD-1) receptor, acting as an immune checkpoint inhibitor to enhance antitumor immune responses. - **BI 754111:** A monoclonal antibody targeting lymphocyte-activation gene 3 (LAG-3), another immune checkpoint protein; this component was included in a triplet regimen in early trials but has since been discontinued. This triplet was studied in a phase I clinical trial setting for advanced/metastatic solid tumors, primarily in patients with biliary tract cancer with MDM2 amplification and TP53 wild-type status. Only one patient in early trials received the full triplet (brigimadlin + ezabenlimab + BI 754111) before discontinuation of BI 754111 from further development[1][4].

Other names

brigimadlin + ezabenlimab + BI 754111